Company: ABBV
Filing Date: 2025-02-18
Form Type: 424B5
Source: 0001104659-25-014554
Chunk: 7

Company: AbbVie Inc.
Filing Date: 2025-02-18
Form: 424B5
Chunk 7
---
 or supersede such information, all of which are incorporated by reference into this prospectus supplement. See “ Where to Obtain More Information .”

#### Risks Related to this Offering
In addition to indebtedness that will be issued in this offering, the Issuer has significant outstanding unused borrowing capacity and significant outstanding debt and may incur additional debt in the future. The terms of such indebtedness could restrict the activities of AbbVie.

As of December 31, 2024, AbbVie had $64.8 billion aggregate principal amount (calculated based on exchange rates in effect as of December 31, 2024) of outstanding unsecured senior notes (the “ Existing Notes ”), including $15.0 billion aggregate principal amount of unsecured senior notes issued in February 2024. The Existing Notes are unsecured, unsubordinated obligations of the Issuer and rank equally in right of payment with all of the Issuer’s existing and future unsecured, unsubordinated indebtedness, liabilities and other obligations. The Issuer may redeem the Existing Notes prior to maturity at redemption prices specified therein, in accordance with their respective terms.

The Issuer entered into a new $3.0 billion five-year revolving credit facility (the “ 2030 Revolving Credit Facility ”) with various financial institutions in January 2025 and an amended and restated $5.0 billion five-year revolving credit facility (the “ 2028 Revolving Credit Facility ” and, together with the 2030 Revolving Credit Facility, the “ Revolving Credit Facilities ”) with various financial institutions in March 2023. In October 2024, the Issuer entered into a new $2.0 billion fixed-rate term loan facility (the “ Term Loan Facility ” and, together with the Revolving Credit Facilities, the “ credit facilities ”) with a financial institution. The proceeds of the Term Loan Facility were used to prepay amounts outstanding under the Issuer’s previous $2.0 billion term loan facility. There are currently no amounts outstanding under the Revolving Credit Facilities and $2.0 billion aggregate principal amount of loans outstanding under the Term Loan Facility. The credit facilities impose restrictions on the Issuer and its subsidiaries, including certain restrictions on their ability to incur liens on their assets. In addition, these credit facilities require the Issuer to maintain compliance with a financial covenant. The Issuer’s ability to comply with these restrictions and covenants may be affected by events beyond its control. If the Issuer breaches any of these restrictions